Overview of screening assays used to evaluate PROTACs for cancer treatment.

Authors

Raghd Obidat, Jazmin Reyes-Martinez, Sara AlRawashdeh, Erika Loredo-Calderon, Carlos A Velázquez-Martínez

Published in

Drug discovery today. Pages 104822. Oct 05, 2026. Epub Oct 05, 2026.

Abstract

Proteolysis-targeting chimeras (PROTACs) are promising anticancer agents, but optimizing them requires screening strategies that go beyond simple target-degradation readouts. This review provides an overview of assays for evaluating anticancer PROTACs and classifies them by their role in the degradation pathway, including target binding and engagement, ternary complex formation, ubiquitination, target degradation and evaluation of anticancer activity in vitro and in vivo. The literature (articles published from 2020 to 2025) shows a strong dependence on degradation endpoints, especially western blotting, and relatively little use of direct ubiquitination assays, ternary complex measurements and quantitative kinetic methods. We highlight knowledge gaps and propose a staged screening framework that integrates mechanistic, quantitative, phenotypic and translational assays to advance the discovery of anticancer PROTACs.

PMID:
42833393
Bibliographic data and abstract were imported from PubMed on 06 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.